Stay updated with breaking news from Lu Endolucinbeta. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
ITM to supply its medical radioisotope, no-carrier-added Lutetium-177, for the clinical development of Y-mAbs' Targeted Radionuclide Therapy candidate GD2-SADA: 177Lu-DOTA Complex for GD2-positive solid
Investegate announcements from ITM Isotope Technologies Munic, ITM Signs Clinical Supply Agreement with Y-mAbs for n.c.a. Lutetium-177
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Molecular Targeting Technologies Inc. (MTTI), a clinical stage biotech company focused on developing innovative
Molecular Targeting Technologies Inc. (MTTI), a clinical stage biotech company focused on developing innovative therapies for rare cancers, and ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical